Publications by authors named "I Bajema"
Objective: A phase II trial tested different doses of the anti-CD40 monoclonal antibody BI655064 as add-on therapy to the standard of care in class III or IV Lupus Nephritis (LN) patients with active disease. A post-hoc analysis showed a potential benefit of the higher tested doses (180mg/240mg) versus low dose (120mg)/placebo. We investigated whether the treatment effect of BI655064 on kidney outcomes may be modified by the presence of glomerular monocytes, a target for this drug with a well-known role in LN pathogenesis.
View Article and Find Full Text PDFArticle Synopsis
- Recurrent IgA deposition after kidney transplantation is common, but it's unclear if it causes organ damage or is harmless.
- A study analyzed kidney transplant recipients with native IgA nephropathy undergoing biopsies from 1995 to 2020, revealing that 37% had recurrent IgA deposition, but there were no substantial clinical differences between those with and without it.
- While recurrent IgA deposition alone didn't lead to graft failure, the presence of the complement factor C4d was linked to higher graft loss risk, indicating its potential pathogenic role in recurrent IgA nephropathy.
Key Points: Nonlupus full house nephropathy is a rare, complex entity: confusion arises by the low-quality evidence and the lack of consensus on nomenclature. This systematic review supports that systemic lupus erythematosus and nonlupus full house nephropathy are distinct clinical entities, with comparable outcomes. The identification of three pathogenetic categories provides further clues for a shared clinical and diagnostic approach to the disease.
View Article and Find Full Text PDF